CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Non-obstructive High-Risk Plaques Increase the Risk of Future Culprit Lesions Comparable to Obstructive Plaques Without High-Risk Features: The ICONIC Study Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention Plaque composition by intravascular ultrasound and distal embolization after percutaneous coronary intervention
|<<... 70 71 72 73 74 75 76 ...>>|

GuidelineJune 13, 2019

JOURNAL：JAMA Article Link

Primary Prevention of Sudden Cardiac Death

A D. Beaser; Adam S. Cifu, MD; Hemal M. Nayak. Keywords: rhythem dysorder; sudden cardiac death; primary prevention; LVEF; heart failure; ventricular fibrillation

ABSTRACT

Ventricular arrhythmias range from benign premature ventricular contractions to ventricular fibrillation and can be asymptomatic or have sudden cardiac death as the first manifestation. Sudden cardiac death is a major public health problem, accounting for 50% of all cardiovascular death.1 Although a plurality of sudden cardiac death occurs in the general population with no apparent cardiac risk factors, the risk is greatest in patients with LVEF of less than 30%, clinical heart failure, prior aborted cardiac arrest, or coronary artery disease.2
>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top